Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

Item
http://www.wikidata.org/entity/Q43202086
Leukemia regression by vascular disruption and antiangiogenic therapy.Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.What role for angiogenesis in childhood acute lymphoblastic leukaemia?Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cellsNF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2)Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies.Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.Raiders of the lost mark - endothelial cells and their role in transplantation for hematologic malignancies.Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
P2860

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

Item
http://www.wikidata.org/entity/Q43202086
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Targeting the angiopoietin (An ...... utive agonistic Ang-1 release.
@en
Targeting the angiopoietin (An ...... utive agonistic Ang-1 release.
@nl
type
label
Targeting the angiopoietin (An ...... utive agonistic Ang-1 release.
@en
Targeting the angiopoietin (An ...... utive agonistic Ang-1 release.
@nl
prefLabel
Targeting the angiopoietin (An ...... utive agonistic Ang-1 release.
@en
Targeting the angiopoietin (An ...... utive agonistic Ang-1 release.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Targeting the angiopoietin (An ...... tutive agonistic Ang-1 release
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921